Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2018

View Archived Issues

FDA grants orphan drug designation to LK-01 for the treatment of AML

XORTX files FDA pre-IND meeting request letter

New Dong-A compound shows activity against resistant Gram-negative bacteria

HIV-1 fusion peptide targeting, a promising vaccination strategy eliciting neutralizing antibodies

Phase III study of Vical's HSV-2 therapeutic vaccine does not meet primary endpoint

Preliminary data presented from interim review of phase I/II study of OXS-1550

Atogepant demonstrates efficacy and safety in phase IIb/III study in episodic migraine

FDA grants fast track designation to Betalutin for relapsed or refractory follicular lymphoma

Significant improvements in ulcerative colitis seen with apremilast in phase II trial

Boehringer Ingelheim initiates phase I study of BI-907828 in solid tumors

Phase III data support ibrutinib/rituximab combination in Waldenstrom's macroglobulinemia

Lilly and AstraZeneca discontinue phase III trials of lanabecestat for Alzheimer's disease

Merck KGaA reports promising phase II data for tepotinib in advanced HCC

EMA grants PRIME designation for Themis' Chikungunya vaccine

First-in-human data on FDL-176 in healthy subjects presented

NeuroRx completes phase IIb/III feasibility enrollment for NRX-101 in suicidal bipolar depression

Merck & Co. patents DGAT2 inhibitors

Arcus Biosciences presents CD73 inhibitors

FDA clears Arcus' INDs for AB-928 and AB-122

Retrotope begins compassionate use trials of RT-001

Aquinox initiates phase II study of rosiptor in chronic prostatitis/chronic pelvic pain syndrome

Takeda launches Azilect in Japan for Parkinson's disease

Apabetalone reverses HIV-1 latency and induces apoptosis of reservoir cells

New nonhuman primate model allows testing of antifibrotic therapeutic candidates

Cancer Research UK advances AST-VAC2 into phase I trial for NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...